top of page

Continuous Molecular Monitoring (CMM) wearables are the next step in medical wearables

after Continuous Glucose Monitoring (CGM) devices

Speaker: Robert Batchelor | Company: Nutromics | Date: 13-14 October 2021 | Full Presentation

There is a clinical need for continuous monitoring of vital molecular biomarkers and drug concentrations. However, with the exception of venous oxygen and glucose, these concentrations are currently determined via lab tests. Lab testing costs valuable time, which is relevant for transient biomarkers and critically sick patients. Additionally, lab testing is intermittent at best, and requires infrastructure, reagents, and skilled operators, which aren’t always available in remote locations.

Electrochemical aptamer-based (EAB) sensors, invented and developed by Prof. Kevin Plaxco at the University of California, Santa Barbara, can be adapted for multiple molecular targets, are reagent-free, and work in-vivo, thus enabling on-body wearable devices. Nutromics is integrating the EAB technology into a wearable ‘lab on the skin’ to meet the pressing clinical need of monitoring molecular biomarkers and drugs.

In this presentation I will discuss the EAB sensor technology, how it compares with continuous glucose monitors, the advantages and limitations of the technology, and finally, the potential of Continuous Molecular Monitoring (CMM) wearable devices using EAB sensors.

Join TechBlick on an annual pass to join all live online conference or online version of onsite conference access library of on-demand talks (600 talks + PDFs)

portfolio of expert led masterclass year-round platform

And do NOT miss our flagship event in Berlin on 17-18 OCT 2023 focused on Reshaping the Future of Electronics. This event attracts 550-600 participants from all the world and offers a superb ambience and dynamic exhibition floor.

To learn more visit

To see feedback about previous event see


Subscribe for updates

Thank you!

bottom of page